164 related articles for article (PubMed ID: 36093581)
21. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study.
Zhao R; Ren S; Li C; Guo K; Lu Z; Tian L; He J; Zhang K; Cao Y; Liu S; Li D; Wang Z
Cancer Med; 2023 Feb; 12(4):5158-5171. PubMed ID: 36161527
[TBL] [Abstract][Full Text] [Related]
22. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
23. A Cross-Sectional and Longitudinal Analysis of Pre-Diagnostic Blood Plasma Biomarkers for Early Detection of Pancreatic Cancer.
Mason J; Lundberg E; Jonsson P; Nyström H; Franklin O; Lundin C; Naredi P; Antti H; Sund M; Öhlund D
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361759
[TBL] [Abstract][Full Text] [Related]
24. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
[TBL] [Abstract][Full Text] [Related]
25. Protein biomarkers in pancreatic juice and serum for identification of pancreatic cancer.
Levink IJM; Visser IJ; Koopmann BDM; van Driel LMJW; Poley JW; Cahen DL; Bruno MJ; Fuhler GM
Gastrointest Endosc; 2022 Nov; 96(5):801-813.e2. PubMed ID: 35537661
[TBL] [Abstract][Full Text] [Related]
26. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
Kruger D; Yako YY; Devar J; Lahoud N; Smith M
PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-analysis.
Kane LE; Mellotte GS; Mylod E; O'Brien RM; O'Connell F; Buckley CE; Arlow J; Nguyen K; Mockler D; Meade AD; Ryan BM; Maher SG
Cancer Res Commun; 2022 Oct; 2(10):1229-1243. PubMed ID: 36969742
[TBL] [Abstract][Full Text] [Related]
29. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
Parikh DA; Durbin-Johnson B; Urayama S
J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
[TBL] [Abstract][Full Text] [Related]
30. CD63-positive extracellular vesicles are potential diagnostic biomarkers of pancreatic ductal adenocarcinoma.
Odaka H; Hiemori K; Shimoda A; Akiyoshi K; Tateno H
BMC Gastroenterol; 2022 Mar; 22(1):153. PubMed ID: 35350978
[TBL] [Abstract][Full Text] [Related]
31. Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma.
Yang CY; Lin RT; Chen CY; Yeh CC; Tseng CM; Huang WH; Lee TY; Chu CS; Lin JT
J Formos Med Assoc; 2022 Dec; 121(12):2601-2607. PubMed ID: 35918272
[TBL] [Abstract][Full Text] [Related]
32. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.
Bhasin MK; Ndebele K; Bucur O; Yee EU; Otu HH; Plati J; Bullock A; Gu X; Castan E; Zhang P; Najarian R; Muraru MS; Miksad R; Khosravi-Far R; Libermann TA
Oncotarget; 2016 Apr; 7(17):23263-81. PubMed ID: 26993610
[TBL] [Abstract][Full Text] [Related]
34. Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma.
Chen J; Chen LJ; Yang RB; Xia YL; Zhou HC; Wu W; Lu Y; Hu LW; Zhao Y
Med Oncol; 2013; 30(2):583. PubMed ID: 23609192
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
van Oosten AF; Groot VP; Dorland G; Burkhart RA; Wolfgang CL; van Santvoort HC; He J; Molenaar IQ; Daamen LA
Ann Surg; 2024 Mar; 279(3):493-500. PubMed ID: 37389896
[TBL] [Abstract][Full Text] [Related]
36. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
37. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis.
Mahajan UM; Oehrle B; Sirtl S; Alnatsha A; Goni E; Regel I; Beyer G; Vornhülz M; Vielhauer J; Chromik A; Bahra M; Klein F; Uhl W; Fahlbusch T; Distler M; Weitz J; Grützmann R; Pilarsky C; Weiss FU; Adam MG; Neoptolemos JP; Kalthoff H; Rad R; Christiansen N; Bethan B; Kamlage B; Lerch MM; Mayerle J
Gastroenterology; 2022 Nov; 163(5):1407-1422. PubMed ID: 35870514
[TBL] [Abstract][Full Text] [Related]
38. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
[TBL] [Abstract][Full Text] [Related]
39. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study.
Brand RE; Persson J; Bratlie SO; Chung DC; Katona BW; Carrato A; Castillo M; Earl J; Kokkola A; Lucas AL; Moser AJ; DeCicco C; Mellby LD; King TC
Clin Transl Gastroenterol; 2022 Feb; 13(3):e00468. PubMed ID: 35166713
[TBL] [Abstract][Full Text] [Related]
40. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]